MedPath

Queen's University at Kingston

Queen's University at Kingston logo
🇨🇦Canada
Ownership
Private
Established
1841-10-16
Employees
1K
Market Cap
-
Website
http://www.queensu.ca

Clinical Trials

314

Active:28
Completed:173

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:21
Phase 2:62
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (289 trials with phase data)• Click on a phase to view related trials

Not Applicable
128 (44.3%)
Phase 2
62 (21.5%)
Phase 4
41 (14.2%)
Phase 3
36 (12.5%)
Phase 1
21 (7.3%)
Early Phase 1
1 (0.3%)

Infection, Prevention and Control: A Multifaceted Approach to Preventing Hospital Acquired Infections Principal

Not Applicable
Completed
Conditions
Infection Prevention
First Posted Date
2025-07-24
Last Posted Date
2025-07-24
Lead Sponsor
Queen's University
Target Recruit Count
50
Registration Number
NCT07083024
Locations
🇨🇦

Queen's University, Kingston, Ontario, Canada

A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.

Not Applicable
Not yet recruiting
Conditions
NMIBC
Non-Muscle Invasive Bladder Urothelial Carcinoma
Bladder (Urothelial, Transitional Cell) Cancer
Urothelial Carcinoma Bladder
Interventions
Drug: Gemcitabine + BCG
Drug: BCG (TICE strain)
First Posted Date
2025-07-15
Last Posted Date
2025-07-17
Lead Sponsor
Queen's University
Target Recruit Count
31
Registration Number
NCT07064863
Locations
🇨🇦

Kingston Health Sciences Center, Kingston, Ontario, Canada

Bone Enhanced Ultrasound (BEUS) Data Library Development Project

Not yet recruiting
Conditions
Lower Back Pain
Facet Joint Pain; Low Back Pain
Osteoarthritis (OA)
First Posted Date
2025-06-25
Last Posted Date
2025-06-27
Lead Sponsor
Queen's University
Target Recruit Count
100
Registration Number
NCT07036653

Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery

Phase 3
Not yet recruiting
Conditions
Pelvic Organ Prolapse (POP)
Interventions
Drug: Vaginal Estrogen - Twice Weekly
Drug: Vaginal Estrogen - Daily
First Posted Date
2025-06-22
Last Posted Date
2025-06-26
Lead Sponsor
Queen's University
Target Recruit Count
180
Registration Number
NCT07030426
Locations
🇨🇦

Health Sciences Centre, St John's, Newfoundland and Labrador, Canada

🇨🇦

Kingston Health Sciences Centre, Kingston, Ontario, Canada

Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD

Phase 1
Not yet recruiting
Conditions
Chronic Pain
Posttraumatic Stress Disorder (PTSD)
Interventions
Behavioral: Mindfulness-based cognitive therapy
First Posted Date
2025-06-06
Last Posted Date
2025-06-06
Lead Sponsor
Queen's University
Target Recruit Count
30
Registration Number
NCT07009158
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 63
  • Next

News

World-First Clinical Trial Demonstrates Exercise Significantly Improves Colon Cancer Survival

A groundbreaking 17-year international clinical trial involving 889 colon cancer patients shows that structured exercise programs reduce cancer recurrence risk by 28% and death risk by 37%.

myeloMATCH Trials Open to Accelerate Precision Medicine for AML and MDS

myeloMATCH, a collaborative effort by leading cancer research organizations, launches clinical trials to advance precision medicine for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Stepped Care Model Shows Promise in Enhancing Adherence to Internet-Based CBT for Depression

A recent study investigated the efficacy of a stepped care model combined with internet-based cognitive behavioral therapy (i-CBT) for adults with major depressive disorder (MDD).

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.